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Introduction
Worldwide the prevalence and characteristics of the met-
abolic syndrome (MS) are linked to immobile lifestyle, con-
sumption of high-calorie “fast food” products, as well as glo-
bal unfavorable environment. According to recent research 
conducted by ARIC (Atherosclerosis Risk in Communities 
Study), the prevalence of metabolic syndrome among men 
and women constitutes 23% and 24%, respectively [1]. In the 
age group from 25 to 45, this pathological state makes up 
35-53,1%. In patients with pathological syndrome the risk 
of cardiovascular complications increases, including myo-
cardial infarction and stroke, which results in mortality, in 
80% of cases MS leads to the development of diabetes mel-
litus [2].
Currently an increase in prevalence of diabetes melli-
tus type 2 (DM-2) is observed in economically developed 
countries. It is known that in patients with DM-2 the risk 
of development of vascular pathology, including coronary 
artery disease, increases by 2-4 times. In turn, combination 
of DM-2 and heart failure boosts the risk of fatal outcome by 
4 times. In MS, as well as in DM, the risk of development of 
cardiovascular complications, including myocardial infarc-
tion and stroke, is very high [3].
Apoptosis plays an important role in the pathogenesis 
of cardiovascular diseases, such as atherosclerosis, cardiac 
ischemia and congestive heart failure [4]. Thus, the extent of 
damage to cardiomyocytes is determined by such pathologi-
cal processes as apoptosis, oxidative stress, as well as meta-
bolic changes. The aim of this work was to study the markers 
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Abstract
Background: The aim of this work is to study the markers of apoptosis (granzyme B) and oxidative stress (nitric oxide), as well as indicators of endothelial 
damage - cystatin C and lipid metabolism in patients with congestive heart failure, and to identify the relationship between these parameters. 
Material and methods: The study included 114 patients (men and women) with congestive heart failure (CHF), out of which 41 patients with CHF, 39 
patients with CHF and diabetes mellitus type 2, and 34 patients with CHF with metabolic syndrome. Biochemical parameters were measured with the 
help of reagent sets produced by “Human” company (Germany), the contents of granzyme B and cystatin C – with the help of commercial sets produced 
by “USCN Life Science Inc” company (China), while nitric oxide concentration was determined using a commercial kit by “R&D System”
Results: Analysis of indicators of apoptosis factors and oxidative stress in studied patients revealed a substantial increase in patients with heart failure 
in the presence of diabetes mellitus type 2, compared to two other groups of patients. The concentration of cystatin 3 in patients with diabetes mellitus 
type 2 increased significantly with *р <0,05.  
Conclusions: The studied parameters allow us to suggest that complications in CHF are due to the intensity of oxidative stress, apoptosis and atherogenesis, 
and are interconnected with biochemical changes in lipid and carbohydrate metabolism.
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of apoptosis (granzyme B) and oxidative stress (nitric oxide), 
as well as indicators of endothelial damage – cystatin C and 
lipid metabolism in patients with CHF and to identify the 
relationship between these parameters.
Material and methods
The research included 114 patients (men and women) 
with congestive heart failure (CHF). Patients were divided 
into 3 groups: I group – 41 patients with CHF, II group – 39 
patients with CHF and DM-2, and III group – 34 patients 
with CHF with metabolic syndrome. 10 healthy patients 
comprised the control group. During the stay in hospital 
laboratory and functional studies were conducted in all pa-
tients, antianginal and antiplatelet therapy was appointed. 
The research was conducted in compliance with the 
Declaration of Helsinki (1975) which was revised in 1989 in 
Hong Kong.
From biochemical indicators in blood plasma the con-
centrations of total cholesterol (TC), α-lipoprotein choles-
terol, β-lipoprotein cholesterol, glycosylated hemoglobin 
(HbAlc), glucose were measured. From apoptosis markers 
granzyme B was determined, from indicators of oxidative 
stress nitric oxide (NO) was measured, as well as cystatin 
C – as atherogenesis factor. Biochemical parameters were 
measured with the help of reagent sets produced by “Hu-
man” company (Germany), the contents of granzyme B and 
cystatin C – with the help of commercial sets produced by 
“USCN Life Science Inc” company (China), while nitric ox-
ide concentration was determined using a commercial kit by 
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“R&D System”. Statistical analysis was conducted with the 
help of Wilcoxon non-parametric criterion (Mann–Whit-
ney test), differences were considered significant at *р <0,05; 
**р<0,01; *** р <0,001 compared to the control value.
Results and discussion
Biochemical data obtained in all studied groups are pro-
vided in table 1, while markers of apoptosis and oxidative 
stress are given in table 2.
As it can be observed, the amounts of lipoprotein com-
plexes, triglycerides and free cholesterol are significantly 
different from the control group. Thus, in the control group 
the level of cholesterol was 2,85 ± 0,21 mmol/l, while the 
level of triglycerides was 1,01 ± 0,14 mmol/l. An increase 
in both indicators was identified during comparison of 
average values in patients with CHF and CHF with meta-
bolic syndrome and diabetes mellitus type 2. Thus, concen-
tration of cholesterol increased up to 4,51 ± 0,23 mmol/l 
(р <0,001) in I group, while in II and III groups – up to 
5,25 ± 0,33 mmol/l and 5,47 ± 0,27 mmol/l, respectively. 
At the same time, the concentration of α-lipoprotein cho-
lesterol declined by 36% in patients in I group, by 45% in 
patients in II group and by 61% in patients in III group. 
Along with this, β-lipoprotein cholesterol increased by 45% 
in patients in I group, by 64% in patients in II group and in 
average by 94% on patients in III group. Hypercholesterol-
emia and hyper-β-lipoproteinemia observed during studies 
contribute to the damage of the vascular endothelium as a 
result of atherogenesis. It was found that high density lipo-
proteins, a major anti-atherogenic fraction of lipoproteins, 
protect endothelial cells from apoptosis, therefore provi- 
ding an important and new dimension of its anti-atherogenic 
activity [5].
Concentration of triglycerides in I group increased by 
3,7 times, in II group – by 4,6 times and in III group – by 
4,1 times, which is consistent with changes in carbohydrate 
metabolism, namely glucose and glycosylated hemoglobin. 
In CHF with DM-2 the content of glucose reached 7,3 ± 1,1 
mmol/l, while in II group this indicator stood at 5,1 ± 1,2 
mmol/l, in III group – at 4,1 ± 0,1 mmol/l. The level of Нв 
А1 in CHF with DM-2 constituted 6,7 ± 0,07%, while in I 
and III groups this indicator was nearly the same and on 
average stood at 5,4 ± 0,01 %.
Thereby, quantitative imbalance between parameters 
of lipid metabolism and lipoprotein complexes, as well as 
dynamics of changes in levels of glucose and glycosylated 
hemoglobin show similar trend in all studied groups of pa-
tients with CHF. Similar results were obtained in the analy-
sis of the average values of nitric oxide and granzyme B in 
patients with CHF (Table 2).
While the control value of nitric oxide was 10,2 ± 0,4 
μmol/l, in all studied groups this parameter increased to the 
following values: 13,7 ± 0,4 μmol/l in I group, 23,4 ± 0,5 
μmol/l in II group, 21,4 ± 0,5 μmol/l in III group.
NO is a short-living molecule which breaks down within 
6-30 seconds. At the same time, NO is recovered by its in-
volvement in dinitrosyl iron complexes with thiol ligands 
or in 8-nitrozols, which may later gradually release NO. 
Such NO-containing complexes are formed in the tissues of 
physiologically active depot. Deposition of NO in the arte-
rial wall begins with any increase of NO levels in the body, 
regardless of its cause. Excess amount of NO at first per-
forms a compensatory function, aimed at improving the tis-
sue perfusion. Later on, there is a transformation of reaction 
into the pathological one with the induction of apoptosis, 
activation of oxidative stress, destructive processes, increas-
ing myocardial dysfunction [6, 7].
Nitric oxide is irreversibly inactivated by the reaction 
with hemoglobin (in oxygenated and dioxygenated forms) 
in the lumen of the blood vessel, by superoxide radical in 
the blood vessel wall or by oxygen in free solution [8, 9]. 
Reaction of nitric oxide with oxygen is accompanied with 
the formation of stable end products – nitrite and nitrate, 
which are indirect markers of concentration of nitric oxide 
in the body [10].
Cathepsins are direct executors of apoptosis, which is 
based on proteolysis caused by cysteine proteases such as 
caspases, cathepsins, granzyme B [11].
Although the content of granzyme B is widely studied in 
immunological disorders, the role of granzyme B/perforin 
system in cardiovascular pathology is insufficiently studied 
[12, 13].
In studied patients concentration of granzyme B sig-
nificantly increased in I group by 1,5 times (р<0,001), in 
II group by 2,5 times (р<0,001), in III group – by nearly 2 
times (р<0,001) in comparison with the control group.
Granzymes enter the target cell through pores formed 
by perforin and trigger apoptosis by activating caspases. 
Granzymes belong to the family of exogenous serine prote-
ases. To date, five classes of granzymes are identified, such 
as A, B, H, K and M. These granzymes are produced in an 
inactive form and are activated by cathepsin C-mediated re-
moval of the propeptide.
Granzymes A and B are the most studied ones. Gran-
zyme B cleaves Asp or Glu residue of pro-caspases, result-
ing in activated caspase cascade, which ultimately leads to 
the death of the target cell. Activated caspases induce DNA 
fragmentation and cell apoptosis [14, 15]. Under normal 
conditions, the system granzyme B/perforin plays an im-
portant role in liquidation of abnormal cells, having anti-
viral activity and participating in the elimination of tumor 
cells. Thus, granzyme plays an important role in CTL-medi-
ated immune response.
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A number of researchers have suggested that granzyme 
B can cleave extracellular matrix [16]. It is assumed that 
granzyme B is involved in chronic, as well as acute inflam-
mation in the atherosclerotic processes in coronary artery. 
It can be assumed that the inhibition of granzyme B can 
introduce a new therapeutic approach to the treatment of 
cardiovascular diseases and such conditions as prevention 
of progression of atherosclerosis, plaque rupture.
To characterize CHF complications we investigated the 
levels of cystatin C and found that the largest increase was 
observed in II group (by 1,8 times), while in I and III groups 
this indicator increased by 1,4 and 1,5 times, respectively. 
The literature shows that increased levels of cystatin C, re-
gardless of other factors, are associated with the severity of 
induced ischemia [17, 18]. Normally cystatin C, as an in-
hibitor of cysteine proteinases, prevents the development 
of atherosclerotic lesions. However, increased level of cys-
tatin C in atherosclerosis may serve as an evidence of large 
atherosclerotic plaques [19, 20]. Cystatin C in patients with 
DM-2 can serve as a reliable predictor of development of 
cardiovascular complications. For instance, it allows to pre-
dict the occurrence of arterial hypertension in patients with 
DM-2 and to some extent to measure the degree of progres-
sion of coronary atherosclerosis in these patients [21, 22].
Thus, it can be concluded that the studied parameters of 
oxidative stress and apoptosis, either individually or in com-
bination, determine the degree of progression of CHF, can 
serve as markers of complications, and are correlated with 
biochemical changes in parameters of lipid and carbohy-
drate metabolism.
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